Platform includes an expanded global library.
Thread Research revealed in a company press release that it has officially launched a suite of new complex electronic clinical outcome assessment (eCOA) features, including an expanded global library, to its decentralized research platform serving global researchers. Reportedly, the new features enable the platform to process complex eCOA data collection while presenting only relevant data to the site teams and participants.
Thread stated that with these new features, clients can now:
"The launch of these enhanced eCOA features provides our clients with the next-generation functionality needed to increase speed, scale consistently, and reduce study risks," said John Reites, co-founder, CEO, Thread, in the aforementioned release. "These features bring us closer to bringing research to everyone, everywhere with our innovative approach to Patient-First eCOA."
Reference: THREAD LAUNCHES SUITE OF NEW FEATURES AND EXPANDED LIBRARY TO MODERNIZE ECOA SOLUTIONS. PR Newswire. September 26, 2023. Accessed September 27, 2023. https://www.prnewswire.com/news-releases/thread-launches-suite-of-new-features-and-expanded-library-to-modernize-ecoa-solutions-301938170.html
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.